Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1611-1617

  Armand, P ^a   Kim, H T ^a   Mayer, E ^a   Cutler, C S ^a   Ho, V T ^a   Koreth, J ^a   Alyea, E P ^a   Antin, J H ^a   Soiffer, R J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myelogenous leukemia; myelodysplastic syndromes; SCT; therapy related disease

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; GYRASE INHIBITOR; METHOTREXATE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; T CELL DEPLETION; WHOLE BODY RADIATION;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78149470761     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.20     Document Type: Article

References (33)

1. Curtis RE, Boice Jr JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-1751.
2. Curtis RE, Boice Jr JD, Stovall M, Bernstein L, Holowaty E, Karjalainen S et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994; 86: 1315-1324. (Pubitemid 24276793)
3. Cadman EC, Capizzi RL, Bertino JR. Acute nonlymphocytic leukemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases. Cancer 1977; 40: 1280-1296. (Pubitemid 8205236)
4. Arseneau JC, Sponzo RW, Levin DL, Schnipper LE, Bonner H, Young RC et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med 1972; 287: 1119-1122.
5. Karchmer RK, Amare M, Larsen WE, Mallouk AG, Caldwell GG. Alkylating agents as leukemogens in multiple myeloma. Cancer 1974; 33: 1103-1107.
6. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70: 1412-1417. (Pubitemid 18026147)
7. Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelo-poietic syndromes in patients with previously treated malig-nant disease. Blood 1981; 58: 759-767.
8. Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 1985; 3: 1640-1658. (Pubitemid 16199216)
9. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195-1204. (Pubitemid 46894010)
10. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008; 26: 1239-1246.
11. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 2009; 18: 343-348.
12. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083-1091. (Pubitemid 20318150)
13. Goldstone A, Burnett A, Avivi I, Hills R, Wheatley K. Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age: AML 10, 11, 12 MRC Trials. Blood 2002; 100: 88a.
14. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3440-3446. (Pubitemid 46594076)
15. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22: 2510-2511. (Pubitemid 41115412)
16. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a conse-cutive series of761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leuke-mia 2002; 16: 2366-2378. (Pubitemid 36067289)
17. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43-52. (Pubitemid 36759634)
18. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB et al. Therapy-related leukemia and myelo-dysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757. (Pubitemid 17226663)
19. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65: 1364-1372. (Pubitemid 15057942)
20. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
21. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336. (Pubitemid 35429670)
22. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic trans-plantation. Biol Blood Marrow Transplant 2007; 13: 655-664. (Pubitemid 46767993)
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088. (Pubitemid 27132124)
24. Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant (e-pub ahead of print 28 September 2009).
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
26. Gray R. A class ofK-sample tests for comparing the cumulative incidence of a competing risk. The Annals ofStatistics 1988; 16: 1140-1154.
27. Fine J, Gray R. A proportional hazards model for the subdistri-bution of a competing risk. JAm Stat Assoc 1999; 94: 496-509.
28. Hoyle CF, de Bastos M, Wheatley K, Sherrington PD, Fischer PJ, Rees JK et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72: 45-53. (Pubitemid 19133767)
29. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ et al. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxo-rubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev 2008; 34: 223-230.
30. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treat-ment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439. (Pubitemid 46594092)
31. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205. (Pubitemid 47232608)
32. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183.
33. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carbo-platin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treatment (Abstract) 2005; 94: S5.